+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cystic Fibrosis - Pipeline Review, H1 2020

  • ID: 5024708
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 502 pages
  • Global Markets Direct

FEATURED COMPANIES

  • AbbVie Inc
  • BioAegis Therapeutics Inc
  • Editas Medicine Inc
  • Invion Ltd
  • Orphomed Inc
  • Sequoia Sciences Inc
  • MORE

Cystic Fibrosis - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis - Pipeline Review, H1 2020, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.

Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 4, 34, 20, 1, 67, 32 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 10, 9 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • BioAegis Therapeutics Inc
  • Editas Medicine Inc
  • Invion Ltd
  • Orphomed Inc
  • Sequoia Sciences Inc
  • MORE
  • Introduction
  • Cystic Fibrosis - Overview
  • Cystic Fibrosis - Therapeutics Development
  • Cystic Fibrosis - Therapeutics Assessment
  • Cystic Fibrosis - Companies Involved in Therapeutics Development
  • Cystic Fibrosis - Drug Profiles
  • Cystic Fibrosis - Dormant Projects
  • Cystic Fibrosis - Discontinued Products
  • Cystic Fibrosis - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Cystic Fibrosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..7), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..8), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..9), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Cystic Fibrosis - Pipeline by 4D Molecular Therapeutics Inc, H1 2020
  • Cystic Fibrosis - Pipeline by AbbVie Inc, H1 2020
  • Cystic Fibrosis - Pipeline by Abeona Therapeutics Inc, H1 2020
  • Cystic Fibrosis - Pipeline by Agile Sciences Inc, H1 2020
  • Cystic Fibrosis - Pipeline by AGILeBiotics BV, H1 2020
  • Cystic Fibrosis - Pipeline by Airway Therapeutics LLC, H1 2020
  • Cystic Fibrosis - Dormant Projects, H1 2020
  • Cystic Fibrosis - Discontinued Products, H1 2020
  • Cystic Fibrosis - Discontinued Products, H1 2020 (Contd..1), H1 2020
List of Figures
  • Number of Products under Development for Cystic Fibrosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
  • 4D Molecular Therapeutics Inc
  • AbbVie Inc
  • Abeona Therapeutics Inc
  • Agile Sciences Inc
  • AGILeBiotics BV
  • Airway Therapeutics LLC
  • Alaxia SAS
  • AlgiPharma AS
  • Altavant Sciences Inc
  • Amgen Inc
  • Antabio SAS
  • Arch Biopartners Inc
  • Arcturus Therapeutics Ltd
  • Armata Pharmaceuticals Inc
  • Arrevus Inc
  • Arrowhead Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atlantic Healthcare Plc
  • Avidin Ltd
  • BioAegis Therapeutics Inc
  • Biofilm Pharma
  • Biolytx Pharmaceuticals Corp
  • Boehringer Ingelheim International GmbH
  • Boston Pharmaceuticals Inc
  • Breathe Easy Therapeutics Ltd
  • BridgeBio Pharma Inc
  • Calista Therapeutics Inc
  • Calithera Biosciences Inc
  • Catabasis Pharmaceuticals Inc
  • Celtaxsys Inc
  • Chiesi Farmaceutici SpA
  • Chrysalis Pharma SAS
  • Cilian AG
  • Copernicus Therapeutics Inc
  • Corbus Pharmaceuticals Inc
  • CRISPR Therapeutics AG
  • CrowdOut Therapeutics
  • CSA Biotechnologies LLC
  • Cyclacel Pharmaceuticals Inc
  • Cyclenium Pharma Inc
  • Daiichi Sankyo Co Ltd
  • Destiny Pharma Plc
  • DiscoveryBiomed Inc
  • Druggability Technologies Holdings Ltd
  • Editas Medicine Inc
  • Eloxx Pharmaceuticals Inc
  • EmphyCorp Inc
  • EnBiotix Inc
  • Enterprise Therapeutics Ltd
  • Entrinsic Health Solutions, Inc.
  • Enzyvant Sciences Ltd
  • Errant Gene Therapeutics LLC
  • Evaxion Biotech ApS
  • Evotec SE
  • Exotect LLC
  • Galapagos NV
  • Galenus Therapeutics Inc
  • Generation Bio Corp
  • Genzyme Corp
  • Grupo Praxis Pharmaceutical SA
  • Helperby Therapeutics Group Ltd
  • Horizon Therapeutics PLC
  • Icagen Inc
  • Idorsia Pharmaceutical Ltd
  • Immun System IMS AB
  • Insmed Inc
  • Invion Ltd
  • Ionis Pharmaceuticals Inc
  • Kamada Ltd
  • Kither Biotech Srl
  • Kyorin Pharmaceutical Co Ltd
  • Lakewood-Amedex Inc
  • Lamellar Biomedical Ltd
  • Laurent Pharmaceuticals Inc
  • MannKind Corp
  • Mariposa Health Ltd
  • Microbion Corp
  • Mucokinetica Ltd
  • Nanogenics Ltd
  • Neupharma Srl
  • New Amsterdam Sciences Inc
  • Novabiotics Ltd
  • Novartis AG
  • Novoteris LLC
  • Omnispirant Ltd
  • Orphomed Inc
  • OrPro Therapeutics Inc
  • Oryn Therapeutics
  • Paranta Biosciences Ltd
  • Parion Sciences Inc
  • Pharmaero ApS
  • Pharmaxis Ltd
  • PhaseBio Pharmaceuticals Inc
  • Polyphor AG
  • Progenra Inc
  • ProQR Therapeutics NV
  • Protalix BioTherapeutics Inc
  • Proteostasis Therapeutics Inc
  • Pulmatrix Inc
  • Rare Partners Srl
  • Recode Therapeutics Inc
  • Renovion Inc
  • Riptide Bioscience Inc
  • Santhera Pharmaceuticals Holding AG
  • SciBac Inc
  • Sequoia Sciences Inc
  • Silurian Pharmaceuticals Inc
  • SolAeroMed Inc
  • Specific Biologics Inc
  • Spirovant Sciences Inc
  • Spyryx Biosciences Inc
  • Synedgen Inc
  • Synovo GmbH
  • Synspira LLC
  • Takeda Pharmaceutical Co Ltd
  • TGV-Inhalonix Inc
  • Therapeutic Systems Research Laboratories Inc
  • Translate Bio Inc
  • Trucode Gene Repair Inc
  • Vast Therapeutics Inc
  • Vectura Group Plc
  • Verona Pharma Plc
  • Vertex Pharmaceuticals Inc
  • Vironika LLC
  • Zambon Co SpA
  • Zata Pharmaceuticals Inc
  • Zikani Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll